Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Brian Koss

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentBiochemistry & Molecular Biology, College of Medicine
Address325 S. Elm St.
Mail Slot # 516
Little Rock AR 72205
Phone501-686-5414
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    1R21CA292278-01     (TACKETT, ALAN J)Jun 1, 2024 - May 31, 2026
    NIH/Nat. Cancer Institute
    Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
    Role: Principal Investigator
    R21CA292278     (TACKETT, ALAN)Jun 1, 2024 - May 31, 2026
    NIH
    Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
    Role: Co-Principal Investigator
    R21AI173759     (BURDINE, MARIE SCHLUTERMAN)Aug 5, 2023 - Jul 31, 2025
    NIH
    DNA-PKcs Regulation of LAT-Mediated Early TCR Signaling in CD4+ and CD8+ T Cells
    Role: Co-Principal Investigator
    DP5OD031863     (KOSS, BRIAN)Sep 14, 2021 - Aug 31, 2026
    NIH
    Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
    Role: Principal Investigator
    1DP5OD031863     (KOSS, BRIAN)Sep 1, 2021 - Aug 31, 2026
    NIH/Office of the Director
    Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
    Role: Principal Investigator
    1DP5OD031863-01     (KOSS, BRIAN)Sep 1, 2021 - Aug 31, 2026
    NIH/Office of the Director
    Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
    Role: Principal Investigator
    5DP5OD031863     (KOSS, BRIAN)Sep 1, 2021 - Aug 31, 2026
    NIH/Office of the Director
    Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
    Role: Principal Investigator
    Early Termination 12/1/2020     (KOSS, BRIAN)Mar 1, 2019 - Feb 28, 2022
    NIH/Nat. Cancer Institute
    Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes
    Role: Principal Investigator
    F31CA232464     (KOSS, BRIAN)Mar 1, 2019 - Feb 28, 2022
    NIH
    Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes- Resubmission
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Xia J, Zhao H, Edmondson JL, Koss B, Zhan F. Role of NEK2 in tumorigenesis and tumor progression. Trends Mol Med. 2024 Aug 23. PMID: 39181803.
      View in: PubMed
    2. Kelliher JL, Folkerts ML, Shen KV, Song W, Tengler K, Stiefel CM, Lee SO, Dray E, Zhao W, Koss B, Pannunzio NR, Leung JW. Evolved histone tail regulates 53BP1 recruitment at damaged chromatin. Nat Commun. 2024 May 31; 15(1):4634. PMID: 38821984.
      View in: PubMed
    3. Frett B, Stephens KE, Koss B, Melnyk S, Farrar J, Saha D, Roy Choudhury S. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia. Cancer Sci. 2024 Mar; 115(3):963-973. PMID: 38226414.
      View in: PubMed
    4. Morehead LC, Koss B, Fil D, Heflin B, Garg S, Wallis KF, Tackett AJ, Miousse IR. Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma. Mol Immunol. 2023 11; 163:188-195. PMID: 37837954.
      View in: PubMed
    5. Azevedo-Pouly AC, Appell LE, Burdine L, Rogers LJ, Morehead LC, Fil D, Barker M, Rainwater RR, Waldrip ZJ, Koss B, Burdine MS. Chemical inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4+ helper and CD8+ effector T cells. Immunol Cell Biol. 2023 08; 101(7):663-671. PMID: 37149747.
      View in: PubMed
    6. Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Curr Oncol Rep. 2023 05; 25(5):479-489. PMID: 36853475.
      View in: PubMed
    7. Roy Choudhury S, Heflin B, Taylor E, Koss B, Avaritt NL, Tackett AJ. CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells. Cells. 2023 02 24; 12(5). PMID: 36899866.
      View in: PubMed
    8. Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719. PMID: 33004350.
      View in: PubMed
    9. Trentzsch M, Nyamugenda E, Miles TK, Griffin H, Russell S, Koss B, Cooney KA, Phelan KD, Tackett AJ, Iyer S, Boysen G, Baldini G. Delivery of phosphatidylethanolamine blunts stress in hepatoma cells exposed to elevated palmitate by targeting the endoplasmic reticulum. Cell Death Discov. 2020; 6:8. PMID: 32123584.
      View in: PubMed
    10. Taylor EM, Koss B, Davis LE, Tackett AJ. Histone Modifications as Biomarkers for Immunotherapy. Methods Mol Biol. 2020; 2055:213-228. PMID: 31502154.
      View in: PubMed
    11. Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, Wang GG. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019 10 03; 134(14):1176-1189. PMID: 31383640.
      View in: PubMed
    12. Chiang TC, Koss B, Su LJ, Washam CL, Byrum SD, Storey A, Tackett AJ. Effect of Sulforaphane and 5-Aza-2'-Deoxycytidine on Melanoma Cell Growth. Medicines (Basel). 2019 Jun 27; 6(3). PMID: 31252639.
      View in: PubMed
    13. Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. J Med Chem. 2019 04 25; 62(8):3971-3988. PMID: 30929420.
      View in: PubMed
    14. Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. 2019 03 15; 79(6):1113-1123. PMID: 30674537.
      View in: PubMed
    15. Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ. Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep. 2017 04 11; 7(1):807. PMID: 28400597.
      View in: PubMed
    16. Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017 Jan; 591(1):240-251. PMID: 27878989.
      View in: PubMed
    17. Koss B, Ryan J, Budhraja A, Szarama K, Yang X, Bathina M, Cardone MH, Nikolovska-Coleska Z, Letai A, Opferman JT. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget. 2016 Mar 08; 7(10):11500-11. PMID: 26862853.
      View in: PubMed
    18. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014 Dec 18; 41(6):947-59. PMID: 25500368.
      View in: PubMed
    19. Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT, Opferman JT. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood. 2013 Aug 29; 122(9):1587-98. PMID: 23881917.
      View in: PubMed
    20. Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013 Jun 15; 27(12):1351-64. PMID: 23788622.
      View in: PubMed
    21. Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol. 2012 Sep 21; 19(9):1175-86. PMID: 22999885.
      View in: PubMed
    22. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, Youle RJ, Green DR, Opferman JT. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion?to respiration. Nat Cell Biol. 2012 Apr 29; 14(6):575-83. PMID: 22544066.
      View in: PubMed
    23. Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol Cell Biol. 2010 Jun; 30(12):3099-110. PMID: 20385764.
      View in: PubMed
    Koss's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (150) concept(s)
    _
    Co-Authors Expand Description
    See all (24) people
    _
    Similar People Expand Description
    See all (43) people
    _
    Same Department Expand Description
    Search Department